약학회지

ISSN 0377-9556 (PRINT)
ISSN 2383-9457 (ONLINE)

Table. 6.

Table. 6.

The number of adverse events of tocilizumab

All adverse events
number (%)
Skin and appendages disorders 98 (25.9)
Rash 34 (9.0)
Pruritus 30 (7.9)
Urticaria 17 (4.5)
Rash erythematous 5 (1.3)
Alopecia 4 (1.1)
Body as a whole-general disorders 55 (14.5)
Anaphylactic reaction 11 (2.9)
Chest pain 10 (2.6)
Fever 7 (1.8)
Rigors 4 (1.1)
Respiratory system disorders 40 (10.6)
Dyspnoea 13 (3.4)
Pharyngitis 6 (1.6)
Pneumonia 6 (1.6)
Coughing 5 (1.3)
Upper respiratory tract infection 4 (1.1)
Liver and biliary system disorders 36 (9.5)
Hepatic enzymes increased 23 (6.1)
SGPT increased 4 (1.1)
SGOT increased 4 (1.1)
White cell and RES* disorders 28 (7.4)
Leucopenia 18 (4.7)
Granulocytopenia 7 (1.8)
Gastro-intestinal system disorders 28 (7.4)
Nausea 11 (2.9)
Vomiting 7 (1.8)
Abdominal pain 6 (1.6)
Central & peripheral nervous system disorders 20 (5.3)
Dizziness 6 (1.6)
Paraesthesia 6 (1.6)
Yakhak Hoeji 2022;66:49-57 https://doi.org/10.17480/psk.2022.66.2.49
© 2022 Yakhak Hoeji